Sensex snaps two days of losses, Ranbaxy soars on U.S. sales

MUMBAI Thu Aug 8, 2013 5:30pm IST

People watch a news channel displayed on a large screen on the facade of the Bombay Stock Exchange building, February 28, 2007. REUTERS/Arko Datta/Files

People watch a news channel displayed on a large screen on the facade of the Bombay Stock Exchange building, February 28, 2007.

Credit: Reuters/Arko Datta/Files

Related Topics

Stocks

   
Priyanka Gandhi Vadra, daughter of Congress party chief Sonia Gandhi, adjusts her flower garlands as she campaigns for her mother during an election meeting at Rae Bareli in Uttar Pradesh April 22, 2014. REUTERS/Pawan Kumar

Election 2014

More than 814 million people — a number larger than the population of Europe — are eligible to vote in the world’s biggest democratic exercise.  Full Coverage 

MUMBAI (Reuters) - The BSE Sensex snapped two days of losses on Thursday, helped by a surge of 27.6 percent in Ranbaxy Laboratories on upbeat quarterly sales in the U.S. at a time when it is facing stringent scrutiny from the drug regulator there, while a rupee recovery also supported the broader market.

Dollar-selling by exporters and expectations of more RBI measures strengthened the beleaguered rupee, adding to the broad market rally.

Stocks have fallen in 10 of the last 12 trading sessions, as investors turn wary of slowing growth and the weakening rupee, which tumbled to a record low on Tuesday despite the central bank's cash-draining measures.

"It's been a tough few weeks to be managing Indian and emerging Asian equities, and sentiment towards India is pretty much at rock bottom at the moment," said Jonathan Schiessl, investment manager of Ashburton Global Funds Chindia Equity Fund.

The Sensex closed 0.67 percent, or 124.46 points, higher at 18,789.34.

The Nifty ended 0.84 percent, or 46.55 points, higher at 5,565.65.

The Nifty has lost 7.3 percent since the RBI first announced the liquidity draining measures on July 15.

Shares in Ranbaxy Laboratories (RANB.NS), India's top drugmaker by sales, zoomed over 30 percent on Thursday after it clocked better-than-expected sales in its key U.S. market.

The results were a relief after its shares had tumbled 36 percent as of Wednesday's close since the drug maker pleaded guilty to U.S. felony charges related to drug safety and agreed to pay $500 million in settlement

Shares in India's top car maker Maruti Suzuki (MRTI.NS) ended 4.07 percent higher after the central bank removed restrictions on shareholding of foreign institutional investors.

Midcap stocks, which have faced the brunt of the recent selloff in equities, also staged a comeback with auto ancillary firm Bharat Forge(BFRG.NS) jumping 16.93 percent.

The NSE Midcap index, which has lost 15 percent since the beginning of June, ended 1.24 percent higher.

However, drugmaker Lupin added to Wednesday's falls, slipping another 3.25 percent to end at 801.35 rupees, while Sun Pharmaceutical Industries Ltd (SUN.NS) dropped 3.13 percent after unit Taro Pharmaceutical Industries Ltd (TARO.N) reported a lower net profit.

(Reporting by Himank Sharma; Editing by Prateek Chatterjee)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Oil Imports

Oil Imports

India to make May-July oil payments to Iran - sources.  Full Article 

DLF Shares

DLF Shares

DLF slides 3 percent, underperforms rivals.  Full Article 

Global Economy

Global Economy

Chinese factories stalling as euro zone business picks up  Full Article 

Rupee Falls

Rupee Falls

Rupee falls for third day; foreign fund inflows key.  Full Article 

Record High

Record High

BSE Sensex hits record high for third straight day.  Full Article 

M&M Upgraded

M&M Upgraded

Credit Suisse upgrades Mahindra & Mahindra to 'outperform'  Full Article 

Breakingviews

Breakingviews

Manchester United’s crisis has silver lining  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage